close X
Patient Portal

Diabetic Retinopathy Clinical Trials

Diabetic Retinopathy Clinical Trials

Retina Specialty Institute is a renowned ophthalmology practice that proudly serves patients across Northwest Florida, Central Florida, Mississippi, and the Alabama Gulf Coast. Our esteemed, skilled eye doctors provide transformative retina care in all aspects of service—from personalized treatments to advanced techniques to state-of-the-art surgical procedures. RSI is the trusted partner of countless people across the US looking to protect and enhance their vision. As part of our commitment to continued advancement and innovation in the ophthalmology field and eye/retina treatment, our practice offers clinical trials on an ongoing basis. Learn more about our current Diabetic Retinopathy clinical trials below and contact us now for any questions or to book an appointment with a physician. You may also visit our clinical trials FAQ page for commonly asked questions and answers.


Yosemite GR4349
A Phase III, Multicenter, Randomizes, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of TO6867461 in Patients With Diabetic Macular Edema

Sponsor: Genentech, Inc.
Retina Specialty Institute PI: Sunil Gupta, MD
Clinicaltrials.gov
Status: Open to enrollment

OPT-302-1003
Phase 1b/2a Study of OPT-302 in Combination With Aflibercept For Persistent Central-Involved Diabetic Macular Edema
Sponsor: Opthea Limited
Retina Specialty Institute PI: Sunil Gupta, MD
Clinicaltrials.gov
Status: Open to enrollment

KalVista KVD001-201
A Randomized, Sham-Controlled, Double-Masked Phase 2a Study of the Efficacy, Safety, and Tolerability of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects with Center-Involving Diabetic Macular Edema (ciDME) Who Have Had Prior Anti-Vascular Endothelial Growth Factor (VEGF) Treatment.
Sponsor: KalVista Pharmaceuticals, Ltd.
Retina Specialty Institute PI: Sunil Gupta, MD
Clinicaltrials.gov
Status: Open to enrollment

Kestrel CRTH258B2301
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients with Visual Impairment Due to Diabetic Macular Edema
Sponsor: Novartis Pharmaceuticals
Retina Specialty Institute PI: Sunil Gupta, MD
Clinicaltrials.gov
Status: Open to enrollment

It’s Time to See...

The Difference Visionary Retina Care Makes